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Background: Frequent exacerbations of chronic obstructive pulmonary disease (COPD) have negative effects on
quality of life and survival. Thus, factors related to exacerbations should be determined. We aimed to evaluate the
effects of thyroid function on quality of life and exacerbation frequency in COPD patients.
Methods: The study population (n = 128) was divided into 3 groups (Group 1: COPD patients with hypothyroidism
(n = 44); Group 2: COPD patients with normal thyroid function tests (n = 44); Group 3: Healthy subjects (n = 40)).
Pulmonary function tests, maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)
measurements were performed. Quality of life questionnaire (Short Form 36, SF-36) was carried out. Patients were
followed up for one year and number of exacerbations was recorded.
Results: FVC, FEV1/FVC, and FEF 25–75% measurements were statistically different between group 1 and 2 (p = 0.041,
p = 0.001, p = 0.009 respectively). Although MEP values were significantly different between group 1 and 2 (p = 0.006),
there was no significant difference in MIP values between groups (p = 0.77). Quality of life scores in group 1 and 2
were significantly lower than control group. Exacerbation frequency was significantly higher in group 1 than in group 2
(p = 0.017). TSH values and exacerbation frequency had positive correlation (p < 0.0001; r = 0.82).
Conclusions: The results of the present study suggest that thyroid function has an effect in exacerbation frequency of
COPD. Decrease in exacerbation numbers with early detection of impairment in thyroid function will have positive
contribution on quality of life in COPD patients.
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Chronic obstructive pulmonary disease (COPD) is a
respiratory disease with systemic complications, which
is characterized by chronic airflow limitation due to
destruction of lung parenchyma and airways [1]. Many
systems including endocrine system are affected in COPD.
Extrapulmonary effects of COPD and comorbidities di-
minish quality of life, aggravate symptoms and increase
mortality [2-4].
Thyroid hormones play an important role in the regu-
lation of thermogenesis and metabolism. Serum thyroid
hormone levels change during systemic illnesses. Previous
studies reported changes in thyroid hormone levels in
respiratory diseases [5]. Hypothyroidism may also cause
alveolar hypoventilation, decreased lung volumes, upper* Correspondence: sevincsarinc@gmail.com
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distribution, and reproduction in any mediumairway obstruction, depression in respiratory stimulus
and respiratory failure. Hypoxia and decreased ventilatory
response to hypercapnia have been demonstrated in
patients with hypothyroidism [6,7]. Diaphragmatic dys-
function and myopathia can be seen in patients with
hypothyroidism. Inspiratory and expiratory muscle strength
is linearly related to the degree of hypothyroidism [8,9].
The myopathic manifestations may be related to impaired
expression of myosin heavy chains IIb or to impaired
neuromuscular transmission [10].
Thyroid function of COPD patients has been investi-
gated in previous studies and different results have been
found [11]. Hypoxia and hypercapnia cause destruction in
sellaturcica and pituitary gland dysfunction. During
the course of COPD, together with hypoxia, peripheral
metabolism of thyroid function changes and thyroid
hormone levels decrease in patients with very severe COPD
[12,13]. Previous studies have also shown altered thyroidntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.mrmjournal.com/content/8/1/64function during COPD exacerbations [14]. To the best
of our knowledge the effects of thyroid function on
acute exacerbations frequency in COPD patients have
not been investigated so far.
We hypothesized that impaired thyroid function may
contribute to the impaired quality of life and increase
exacerbation frequency in COPD patients. Thus we
aimed to investigate quality of life in COPD patients
with and without hypothyroidism and to determine a
relationship between acute exacerbations frequency and
thyroid function.Methods
A prospective case control study was conducted in COPD
patients. Institutional review board of our university
approved the protocol and informed consent form was
signed by each participant.Study population
COPD patients who have been regularly followed up at
outpatient clinics of Pulmonary Diseases Department of
Baskent University Faculty of Medicine in Ankara, Turkey,
between August 2009 and December 2010 were recruited
to the study. Medical history, physical examination,
pulmonary function tests (PFTs), chest X-rays; thyroid
function test results of all patients were recorded in order
to establish the diagnosis of COPD and hypothyroidism.
Diagnosis of COPD was based on current Global Ini-
tiative for Chronic Obstructive Lung Disease (GOLD)
guidelines [1]. All COPD patients were ex-smokers and
stable at the time of the enrollment in the study. Patients
with mild, moderate and severe obstruction were recruited
to the study.
COPD patients with impaired thyroid function test re-
sults were examined in the department of endocrinology.
Further diagnostic investigation was performed if needed
in patients with hypothyroidism to reach an accurate
diagnosis.
Patient groups (COPD patients with and without hypo-
thyroidism) were composed of patients with similar age,
gender and degree of airflow obstruction. The number of
patients with severe airflow obstruction was the same in
each group. Patients with severe obstruction received
additional inhaled corticosteroid treatment.
Patients during acute exacerbation of COPD, and who
received systemic corticosteroids, medications containing
iodine, amiadorone and/or contrast material within prior
two months, those who could not perform the pulmonary
function tests, those with thyroid surgery, other endocrine
diseases (including diabetes mellitus), neuromuscular and
cardiovascular diseases, symptoms of any infections or
using anti-inflammatory medications, and patients with
hypoxemia were excluded from the study.Age and gender matched control subjects were selected
from healthy subjects with normal thyroid function and
without any systemic diseases and smoking history.
We divided study population (n = 128) into three groups
(Group 1: COPD patients with hypothyroidism (n = 44),
Group 2: COPD patients with normal thyroid functions
(n = 44), Group 3: Healthy subjects (n = 40)).
Thyroid function tests
Venous blood samples were collected into blood collection
tubes with red cap at 8 a.m. following an overnight fast.
Thyroid stimulating hormone (TSH) (normal range:
0.35–4.0 mIU/L), free triiodothyronine (FT3) (normal
range: 2.3–6.7 pmol/L) and free tetraiodothyronine
(FT4) (normal range: 10.2–24.4 pmol/L) were mea-
sured with using electrochemiluminescence immuno-
assay (E170, Mannheim, Germany). Patients with elevated
serum TSH levels (higher values than 4.0 mIU/ml) and a
low serum FT4 concentration were diagnosed as primary
hypothyroidism, whereas patients with normal FT4 con-
centration in the presence of an elevated TSH concentra-
tion were diagnosed as subclinical hypothyroidism.
Patients with secondary (central) hypothyroidism had a low
serum FT4 concentration and a serum TSH concentration
that was not appropriately elevated. 32 COPD patients with
primary hypothyroidism, 4 COPD patients with secondary
hypothyroidism, and 8 COPD patients with subclinic hypo-
thyroidism were included in the study.
Pulmonary function tests
Pulmonary function tests were performed with a clinical
spirometer (SensorMedicsVmax spectra 229, Bilthoven,
The Netherlands). Maximal expiratory flow maneuver
was performed by patients and control subjects. Forced
expiratory volume in 1 second (FEV1) and forced vital
capacity (FVC) values were obtained and FEV1/FVC was
calculated. Standard PFTs including spirometry and lung
volumes were evaluated according to the previously de-
scribed guidelines [15]. Patients with post-bronchodilator
FEV1/FVC <70%, and irreversible airflow obstruction were
recruited to the study [16]. Post-bronchodilator FEV1
values were used to define disease stage according to
the GOLD severity classification [1].
Evaluation of respiratory muscle strength
Respiratory muscle strength was assessed by measuring the
maximal inspiratory pressure (MIP) reflecting the strength
of the diaphragm and other inspiratory muscles, and the
maximal expiratory pressure (MEP) reflecting the strength
of the abdominal muscles and other expiratory muscles
[17]. A hand-held Micro RPM (respiratory pressure meter)
was used to measure respiratory muscle strength [18]. The
technician explained the procedure before the test and
demonstrated the correct manoeuvre.
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The SF-36 questionnaire was used to evaluate quality
of life (QOL). This questionnaire has been previously
validated for COPD patients [19,20]. The subjects’ daily
routine activities, social life and exercise performance
were determined based on 36 questions of this item. Main
eight domains as physical function, social function, physical
and emotional role limitation, mental health, pain, vitality,
and general health perception were found. A computer al-
gorithm was used to score the responses to the SF-36 [21].Acute exacerbation frequency
Diagnosis of an exacerbation relies on clinical presenta-
tion of the patient complaining of worsening symptoms
(dyspnea, cough or sputum production) and leading to
an increase in the use of maintenance medications and/or
supplementation with additional medications that is beyond
normal day to day variations [1]. All patients were followed
up for one year after the enrollment to the study and
number of exacerbations was recorded. The data regarding
the exacerbation frequency were collected via regular out-
patient visits every 3 months, hospitalizations, emergency
room admissions and telephone calls on a thorough review
of patient’s symptoms.Statistical analysis
The statistical analyses of our study were performed using
SPSS statistical software version 20.0. The variables were
investigated using visual (histograms, probability plots)
and analytical methods (Kolmogorov Smirnov test) to de-
termine the normality of distributions. The results were
expressed as mean ± standard deviation and median value
(min-max range). ANOVA was used to compare parame-
ters with normal distribution among study groups (group
1, 2, and 3). Levene’s test was used to assess homogeneity
of variances. P less than 0.05 was accepted as significance
level. When an overall significance was observed pairwise
post hoc tests were performed using Tukey’s test for ho-
mogenous variances and Tamhane’s T2 test for heterog-
enous variances. For continuos variables without normal
distribution Mann–Whitney U test was used for the com-
parison of the two groups (patients with and without
hypothyroidism), whereas Kruskal-Wallis test for the
comparison of parameters among 3 groups. T- test was
used for the comparison of parameters with normal distri-
bution between 2 groups. The parameters affecting acute
exacerbation frequency were investigated using Pearson
and Spearman correlation analysis. Fisher’s exact test was
used to compare disease stages in two groups.
A multiple linear regression model was used to identify
independent predictors of acute exacerbation frequency.
The model fit was assessed using appropriate residual and
goodness of fit statistics.Results
Demographic data and pulmonary function test results
of our study population are demonstrated in Table 1.
Age, body mass index (BMI), height and weight were
not different among study groups. Post hoc analysis showed
that MEP values were significantly different between group
1 and 2, and group 2 and 3 (p = 0.006; p = 0.018 respect-
ively). Cigarette pack/year, FEV1/FVC, FVC (liter and %),
and FEF%25–75 were significantly different among the three
groups (Table 1) (group 1 vs 2, group 1 vs 3, group 2 vs 3).
We also compared pulmonary function test results of
group 1 and 2 and did not find statistically significant dif-
ference in terms of FEV1 (L and %) (p = 0.637, p = 0.339,
respectively).
FVC (litre), FEV1/FVC, FEF%25–75 (litre/sec) were
significantly different between group 1 and 2 (p = 0.041,
p = 0.001, p = 0.009, respectively). We found a signifi-
cant difference in MEP values between group 1 and 2
(p = 0.006), but not in MIP values (p = 0.77). TSH
values were significantly different between group 1 and
2 (p = 0.04) (Table 2). Disease stage of patients in group
1 and 2 was not different (p = 0.169) (Table 3).
SF 36 scores in group 1 and 2 were significantly lower
than in control group (Table 1). There were no significant
differences between Group 1 and 2 in terms of SF 36
scores (Tables 1, 2). We found positive significant correla-
tions between FEV1 (L) and scores of SF-36 domains
(FEV1 with physical activity p < 0.0001, r = 0.582; FEV1
with physical role limitation p < 0.0001, r = 0.488; FEV1
with general health p < 0.0001 r = 0.534; FEV1 with vitality
p < 0.0001 r = 0.434; FEV1 with social functioning p <
0.0001, r = 0.534; FEV1 with emotional role limitation
p = 0.001 r = 0.412; FEV1 with mental health p = 0.001,
r = 0.398).
Acute exacerbation frequency of group 1 was significantly
higher than that of group 2 (1.5 ± 0.85 and 0.86 ± 0.83
respectively; p = 0.017) (Table 2).
When we evaluated the relationships between TSH
values and demographic data and SF 36 domains, we
found significant relationships between TSH and BMI and
mental health (p = 0.033, r = −0.323; p = 0.037, r = −0.315;
respectively). There were no significant correlations be-
tween TSH and MIP, MEP, FEV1 L and FVC L (p = 0.146,
r = −0.228; p = 0.117, r = −0.246; p = 0.906, r = −0.018;
p = 0.405, r = −0.129; respectively).
Acute exacerbation frequency was not correlated with
MIP and MEP values (p = 0.51, r = −0.103; p = 0.167,
r = −0.214 respectively). FVC L, FVC%, FEV1 L, FEV1%
were negatively correlated with exacerbation frequency
(p = 0.008, r = −0.391; p = 0.002, r = −0.448; p = 0.01,
r = 0.380; p = 0.042, r = −0.304 respectively).
A positive significant relationship between acute exacer-
bation frequency and TSH values was found (p < 0.0001;
r = 0.82) (Figure 1). Multiple linear regression model was
Table 1 Demographic data, pulmonary function test and SF-36 results of the study population
PARAMETERS COPD + Hypothyroidism COPD CONTROL P
Group 1 Group 2 Group 3
(n = 44) (n = 44) (n = 40)
Age (years) 64.1 ± 7.1 66.5 ± 6 64.7 ± 3.4 0.26
Gender (F/M) 22/22 22/22 20/20 1
Height (cm) 162.7 ± 7.2 166.2 ± 7.3 167 ± 8.4 0.11
Weight (kg) 78.7 ± 15.8 76.1 ± 17.1 78.5 ± 12.2 0.9
BMI (kg/m2) 29.73 ± 5.74 27.43 ± 5.35 27.88 ± 3.98 0.296
Cigarette pack/year 37.6 ± 22.6a,b 54.2 ± 26.7a,c 0bc <0.0001
FEV1/FVC 67.2 ± 11.1
a,b 53.2 ± 15.6a,c 79.5 ± 5.2b,c <0.0001
FEV1(L) 2.1 ± 0.7
a 2.01 ± 0.53b 3.6 ± 0.58 a,b <0.0001
FEV1(%) 83.1 ± 22.2
a 77.5 ± 16.2b 116.9 ± 17.5 a,b <0.0001
FVC (L) 3.1 ± 0.9a,b 3.67 ± 0.9a,c 4.6 ± 0.8 b,c <0.0001
FVC (%) 100.1 ± 19.2a 108.9 ± 21b 121.8 ± 19.6 a,b 0.003
FEF25–75 (%) 47.5 ± 27.4
a,b 29.6 ± 12.3a,c 95.1 ± 21.9 b,c <0.0001
TLC (%) 107.2 ± 19.5 105.3 ± 19 113.9 ± 15.9 0.22
TLC (L) 5.9 ± 1.4 6.5 ± 1.5 6.55 ± 1.03 0.32
MIP (cmH2O) 69.6 ± 30.7 67.3 ± 17.5 74.05 ± 24.3 0.673
MEP (cmH2O) 25.6 ± 9.1
a,b 34.9 ± 11.5a,c 26.7 ± 6.4b,c 0.004
General health 35 (0–80)a 45 (10–70)b 69.5 (40–82)a,b <0.0001
Physical functioning 52.5 (0–100) a 62.5 (25–95) b 90 (50–100) a,b <0.0001
Physical Role limitation 25 (0–100) a 25 (0–100) b 100(50–100)a,b <0.0001
Emotional Role limitation 33 (0–100) a 33 (0–100) b 66.6(0–100) a,b <0.0001
Social functioning 50 (13–100) a 56 (0–100) b 87.5(38100)a,b <0.0001
Pain 60 (0–100) a 85 (20–100) b 100(40–100)a,b 0.029
Vitality 52.5 (10–85) a 57.5 (20–92) b 80.5(45100)a,b 0.001
Mental health 52.5 (12–80) a 58 (15–90) b 72 (50–95) a,b <0.0001
Data are expressed as mean ± SD for parameters with normal distribution and median for parameters with skewed distribution (range min-max).
Where P is significant, values within a row with the same superscript letter are significantly different.
BMI, Body mass index; COPD, Chronic obstructive pulmonary disease; F/M, Female/Male; FEF25–75%, Forced expiratory flow at 25–75%; FEV1, Forced expiratory
volume at 1 second; FVC, Forced vital capacity; MEP, Maximal expiratory pressure; MIP, Maximal inspiratory pressure; SF-36, Short form-36; TLC, Total lung capacity.
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frequency. Only TSH was found to be significantly asso-
ciated with acute exacerbation frequency (p < 0.0001)
(Table 4).
Discussion
To our knowledge, the present study is the first one
investigating quality of life and exacerbation frequency
in COPD patients with and without hypothyroidism
and the relationships between thyroid functions and
exacerbation frequency in COPD patients.
Dyspnea, exercise limitation, depressed psychological
mood, comorbidities and exacerbations are main factors
affecting quality of life in COPD patients [22]. Increased
perception of dyspnea decreases physical activity and
dyspnea aggravates during limited physical activities so
as a vicious cycle is formed. Evaluation of quality of lifein COPD patients with SF-36 questionnaire is an easy
and helpful method already demonstrated in previous
studies [23,24]. We determined significantly decreased
scores of SF-36 domains in COPD patients with and
without hypothydroidism than in control subjects and
FEV1 values were significantly correlated with SF-36
scores in accordance with the previous studies [25,26].
In a recent population based study thyroid hormone
status and health related quality of life were investigated
and scores of subjects with suppressed TSH values or
markedly elevated TSH values were not significantly lower
than those of subjects with normal or mildly elevated TSH
values [27]. However, to our knowledge, up until our study
the quality of life in COPD patients with and without
hypothyroidism has not been evaluated. In the present
study SF-36 scores of COPD patients with and without
hypothyroidism did not differ significantly. Therefore we
Table 2 Pulmonary function tests, muscle strength,
thyroid function tests, SF-36 results and acute
exacerbation frequency of COPD patients with and
without hypothyroidism (Group 1 and 2)
PARAMETERS COPD + Hypothyroidism COPD P
Group 1 Group 2
(n = 44) (n = 44)
FEV1/FVC 67.2 ± 11.1 53.2 ± 15.6 0.001
FEV1(L) 2.1 ± 0.7 2.01 ± 0.53 0.637
FEV1(%) 83.1 ± 22.2 77.5 ± 16.2 0.339
FVC (L) 3.1 ± 0.9 3.67 ± 0.9 0.041
FVC (%) 100.1 ± 19.2 108.9 ± 21 0.15
FEF25–75 (%) 47.5 ± 27.4 29.6 ± 12.3 0.009
TLC (%) 107.2 ± 19.5 105.3 ± 19 0.76
TLC (L) 5.9 ± 1.4 6.5 ± 1.5 0.306
MIP (cmH2O) 69.6 ± 30.7 67.3 ± 17.5 0.77
MEP (cmH2O) 25.6 ± 9.1 34.9 ± 11.5 0.006
TSH (mIU/mL) 4.3 (0.1–16.8) 0.8(0.3-3.6) 0.04
FT4 (pmol/L) 2.15 ± 3.27 2.36 ± 3.56 0.87
FT3 (pmol/L) 2.37 ± 0.77 2.73 ± 0.84 0.27
Acute exacerbation
frequency (/years)
1.5 ± 0.85 0.86 ± 0.83 0.017
General health 35 (0–80) 45 (10–70) 0.383
Physical functioning 52.5 (0–100) 62.5 (25–95) 0.391
Physical role limitation 25 (0–100) 25 (0–100) 0.637
Emotional role
limitation
33 (0–100) 33 (0–100) 0.608
Social functioning 50 (13–100) 56 (0–100) 0.972
Pain 60 (0–100) 85 (20–100) 0.179
Vitality 52.5 (10–85) 57.5 (20–92) 0.548
Mental health 52.5 (12–80) 58 (15–90) 0.249
Data are expressed as mean ± SD for parameters with normal distribution and
median for parameters with skewed distribution (range min-max).
COPD, Chronic obstructive pulmonary disease; FEF25–75%, Forced expiratory
flow at 25–75%; FEV1, Forced expiratory volume at 1 second; FT3, Free
triiodothyronine; FT4, Free tetraiodothyronine; FVC, Forced vital capacity; MEP,
Maximal expiratory pressure; MIP, Maximal inspiratory pressure; SF-36, Short
form-36; TSH, Thyroid stimulating hormone.
Table 3 Comparison of group 1 and 2 in terms of disease
severity
Disease stage COPD + Hypothyroidism COPD P
Group 1 Group 2
(n = 44) (n = 44)
STAGE 1 30 22 0.169
STAGE 2 10 18
STAGE 3 4 4
COPD, Chronic obstructive pulmonary disease.
Figure 1 Relationship between thyroid stimulating hormone
(TSH) levels and acute exacerbation frequency of COPD.
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quality of life in COPD patients. This result should be
addressed in the future prospective investigations with
larger sample size of COPD patients.
In several diseases, the evaluation of respiratory muscle
strength is very useful. It is known that a reduction of MIP
and MEP has been associated with several neuromuscular
diseases, but it is also possible to detect decreased values
of MIP and MEP in COPD patients [28]. Malnutrition,
muscular atrophy, steroid-induced myopathy, pulmonary
hyperinflation and reduced blood flow to the respiratory
muscles are contributing factors to respiratory muscle
weakness in COPD patients [29-31]. Diaphragmatic dys-
function in hypothyroidism, and inverse relationship
between TSH and inspiratory and expiratory muscles’
length have been previouslyreported [7-9]. In the present
study MEP values were significantly lower in patients with
hypothyroidism than in those without it. This result con-
firms the adverse effects of hypothyroidism on expiratory
muscles. However we did not find a significant differenceTable 4 Multiple linear regression model for exacerbation
frequency
Multiple linear regression model for exacerbation
frequency by TSH, FEV1 (L and %) and FVC (L and %)
Coefficient B value Standard error t P
Constant 0.611 1.51 0.403 0.689
TSH levels 0.918 0.102 9.02 <0.0001
FEV1 (L) −3.402 2.74 −1.23 0.223
FEV1(%) 0.099 0.076 1.303 0.201
FVC (L) 1.39 1.59 0.874 0.388
FVC (%) −0.061 0.056 −1.089 0.283
COPD, Chronic obstructive pulmonary disease; FEV1: Forced expiratory volume
at 1 second; FVC, Forced vital capacity; TSH, Thyroid stimulating hormone.
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thyroidism and no significant correlation between MIP
and MEP values and thyroid function. These results might
be due to the characteristics of our study population as we
did not include patients with very severe COPD, with hyp-
oxemia and neuromuscular disorders, or those who have
received systemic corticosteroids. Besides, similar FEV1
values and disease stages of COPD patients with and with-
out hypothyroidism may affect these outcomes.
Exacerbations of COPD are important events in the
course of disease as exacerbations negatively affect quality
of life, accelerate the decline of pulmonary function,
and are associated with higher socioeconomic costs
and mortality [1,32]. Development of strategies to prevent
exacerbations is an important goal in COPD. In the
present study we determined that exacerbation frequency
in COPD patients with hypothyroidism was significantly
higher than in COPD patients without hypothyroidism
and we detected a significant relationship between TSH
values and frequency of acute exacerbations. Moreover,
we strengthened our hypothesis with linear regression
analysis, because we found that the only significant deter-
minant of exacerbation frequency was serum TSH levels
in our study population.
Limitations
The limitation of our study was failure to convince higher
number of patients to participate in the study. Further
studies with larger sample sizes are needed to confirm and
explore the findings of the present study.
Conclusions
In conclusion, our preliminary study demonstrates a
significant relationship between TSH levels and COPD
exacerbation frequency which suggests that the detection of
impairment in thyroid function can decrease exacerbation
number and improve quality of life in COPD patients.
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